# A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

> **NCT05096221** · PHASE3 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 126 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** delandistrogene moxeparvovec
- **GENETIC:** placebo

## Key facts

- **NCT ID:** NCT05096221
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2023-10-04
- **Final completion:** 2024-10-25
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096221, "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05096221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*